SpyGlass Pharma reports promising clinical trial results for glaucoma therapy
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up
Vision loss due to Glaucoma can be prevented if it is detected and treated early
First of its kind screening for Glaucoma at grass root level over 10k screened already
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
Raising awareness about glaucoma is crucial in India where it is the leading cause of irreversible blindness with at least 12 million people affected and almost 1.2 million people blind from the disease
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Subscribe To Our Newsletter & Stay Updated